Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acetylcholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 0.95 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.91 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.91 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.91 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.91 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.91 |
| ▸ | HTR1A | P08908 | 2/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.91 |
| ▸ | PGR | P06401 | 1/20 | 0.91 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.91 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.91 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.91 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.91 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.91 |
| ▸ | GALR3 | O60755 | 2/20 | 0.86 |
| ▸ | GAA | P10253 | 1/20 | 0.86 |
| ▸ | RAB9A | P51151 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcholine SCHEMBL27920125 | 0.98 | CHRM5 (1.00) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Acetylcholine SCHEMBL9303735 | 0.98 | CHRM1 (0.95) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Acetylcholine SCHEMBL40885 | 0.98 | CHRM5 (1.00) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Acetylcholine SCHEMBL27479902 | 0.95 | CHRM5 (0.95) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Acetylcholine SCHEMBL27591882 | 0.95 | CHRM5 (0.95) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Acetylcholine SCHEMBL5468500 | 0.95 | CHRM5 (0.95) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Acetylcholine SCHEMBL31072232 | 0.95 | CHRM5 (0.95) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Acetylcholine SCHEMBL2518957 | 0.95 | CHRM1 (1.00) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Acetylcholine SCHEMBL3216 | 0.95 | CHRM1 (1.00) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Acetylcholine SCHEMBL1899186 | 0.93 | CHRM1 (0.95) | CHRM5CHRM1CHRM3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539221-B2 | Method of treating airway diseases with β-adrenergic inverse agonists | EGB ADVISORS, LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-20100286224-A1 | METHOD OF TREATING AIRWAY DISEASES WITH BETA-ADRENERGIC INVERSE AGONISTS | MCP MANAGER PTY LTD, AS TRUSTEE FOR AND FOR THE BENEFIT OF THE MCP UNIT TRUST 2014 (AU) | 2010-11-11 | — | — | US | disclosed |
| US-7528175-B2 | Method of treating airway diseases with beta-adrenergic inverse agonists | INVERSEON, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080254022-A1 | Method of Treating Airway Diseases With Beta-Adrenergic Inverse Agonists | INVERSEON, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070276024-A1 | Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists | INVERSEON , INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20060194882-A1 | Method of treating airway diseases with beta-adrenergic inverse agonists | MCP MANAGER PTY LTD, AS TRUSTEE FOR AND FOR THE BENEFIT OF THE MCP UNIT TRUST 2014 (AU) | 2006-08-31 | — | — | US | disclosed |
| EP-1684764-A2 | METHODS FOR TREATING DISEASES AND CONDITIONS WITH INVERSE AGONISTS AND FOR SCREENING FOR AGENTS ACTING AS INVERSE AGONISTS | Inverseon, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1677778-A2 | METHOD OF TREATING AIRWAY DISEASES WITH BETA-ADRENERGIC INVERSE AGONISTS | Inverseon, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035731-A2 | METHODS FOR TREATING DISEASES AND CONDITIONS WITH INVERSE AGONISTS AND FOR SCREENING FOR AGENTS ACTING AS INVERSE AGONISTS | INVERSEON, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005034871-A2 | METHODS FOR TREATING DISEASES AND CONDITIONS WITH INVERSE AGONISTS | INVERSEON, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276024-A1 | Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists | MRGPRX2, MRGPRX1, GPR52 | CHRM3 170/4885CHRM5 405/4885CHRM1 439/4885 |
| US-20100286224-A1 | METHOD OF TREATING AIRWAY DISEASES WITH BETA-ADRENERGIC INVERSE AGONISTS | ADRB2, ADRB1, ADRA2B | CHRM3 23/4885CHRM5 62/4885CHRM1 37/4885 |
| US-20060194882-A1 | Method of treating airway diseases with beta-adrenergic inverse agonists | ADRB2, ADRB1, ADRA2B | CHRM3 23/4885CHRM5 62/4885CHRM1 37/4885 |
| US-20080254022-A1 | Method of Treating Airway Diseases With Beta-Adrenergic Inverse Agonists | ADRB1, ADRB2, ADRB3 | CHRM3 24/4885CHRM5 79/4885CHRM1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.